# Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study

> **NCT03785067** · PHASE3 · TERMINATED · sponsor: **The George Institute** · enrollment: 1 (actual)

## Conditions studied

- Cognitive Decline
- Intracerebral Hemorrhage
- Dementia, Vascular
- Cerebral Small Vessel Diseases
- Hypertension
- Stroke Hemorrhagic

## Interventions

- **DRUG:** telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03785067
- **Lead sponsor:** The George Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-27
- **Primary completion:** 2021-02-03
- **Final completion:** 2021-02-03
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Contractual and financial issues.
- **Last updated:** 2021-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03785067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03785067, "Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03785067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*